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CC BY-NC-ND license (http://creativeAbstract To determine the optimal number of cycles of docetaxel for metastatic castration-
resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers
of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival,
prostate-specific antigen (PSA) response, and adverse events. The study included 33 patients
receiving  10 cycles of docetaxel and 40 patients receiving > 10 cycles. Patients receiving >
10 cycles were younger than those who received  10 cycles. There was no statistical signif-
icant difference in overall survival between the two groups (log-rank test, pZ 0.75). Adverse
effects were more common among patients receiving  10 cycles of treatment. A PSA flare-up
was observed among six patients (8.2%); the median duration of the PSA surge was 3 weeks
(range, 3e12 weeks). The overall survival rates in patients with PSA flare-up were comparable
with the patients having PSA response. We concluded that at least four cycles of docetaxel
should be administered in metastatic castration-resistant prostate cancer patients in order
not to cease treatment prematurely from potentially beneficial chemotherapy. However,
administering > 10 cycles does not result in any further improvement in survival and is associ-
ated with more adverse effects.
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Castration-resistant prostate cancer (CRPC) generally has a
poor prognosis and results in significant morbidity and
mortality. Chemotherapy has been the first-line treatment
for metastatic CRPC (mCRPC) since 2004, and docetaxel-
based regimens have been shown to improve both patient
symptoms and survival [1e3]. Docetaxel plus prednisolone
(DP) administration every 3 weeks is now established as a
first-line therapy for CRPC, and results in the best overall
survival (OS) [1,3]. Between 2004 and 2010, there were no
second-line agents available that could improve survival
after docetaxel failure. Moreover, the optimal number of
treatment cycles when administering docetaxel has always
been disputed. Some studies reported that a considerable
portion of patients experienced an initial prostate-specific
antigen (PSA) surge without clinical disease or symptom
progression, and then subsequently showed PSA decline,
called PSA flare phenomenon. All studies showed that PSA
flare-up did not have a negative effect on survival
compared with the initial PSA response group [4e6], which
made it unnecessary to stop chemotherapy prematurely
only due to initial PSA increasing. Furthermore, in the TAX-
327 [3] and SWOG 99-16 [1] studies, up to 11 or 12 cycles of
docetaxel-based chemotherapy were administered, after
which disease progression, severe adverse events, or death
occurred. Therefore, a treatment regimen of approxi-
mately 10 cycles became accepted clinical practice. How-
ever, the potential advantages or disadvantages of
extending treatment beyond 10 cycles remain unknown.
After 2011, agents that extended survival for patients with
CRPC were developed [7,8], and it has therefore become
more important to determine the optimal duration of
docetaxel treatment and hence to better understand when
second-line therapy with these new agents should be
initiated. The aim of this study was to determine the
optimal number of treatment cycles by analyzing the sur-
vival outcome, PSA response, and adverse events of pa-
tients receiving DP every 3 weeks; to identify the benefits
of extending DP treatment beyond 10 cycles; and to eval-
uate the impact of a PSA flare-up.
Materials and methods
Through retrospective chart review (Chang Gung Institu-
tional Review Board approved) we selected patients with
mCRPC who had received three cycles or more than of
docetaxel, and had image-proved bone, lymph node, or
visceral metastases. Eligible patients had an Eastern
Cooperative Oncology Group performance status of 0e2
(patients with a performance status of 3 due to bone pain
were also eligible). Premedication with 8-mg dexametha-
sone followed by docetaxel (Taxotere, Aventis) at 75 mg/
m2 was administered, together with oral prednisolone twice
daily, in accordance with the TAX-327 regimen [1]. The
dose was reduced to 60 mg/m2 if the serum level of alanine
aminotransferase (AST) and aspartate aminotransferase
(ALT) increased to 1.5e3.5 times the upper limit or
hyperbilirubinemia. In addition, if there had been febrile
neutropenia in a previous cycle, treatment was delayed by
up to 3 weeks or until the neutrophil count exceeded 1500/mm3. Chemical androgen deprivation therapy was
continued during chemotherapy for patients who had not
undergone an orchiectomy. Bisphosphonate treatment was
also prescribed for patients with significant bone pain
associated with bony metastases.
Follow-up and outcome
Blood tests for the assessment of PSA, complete blood
count, renal function, and liver function were repeated
every 3 weeks on Day 1 before chemotherapy. The PSA
response was categorized by the magnitude of the change
in PSA level. The responder group was defined by a reduc-
tion of serum PSA level by at least 50% from baseline,
whereas the Nonresponder group was defined by PSA pro-
gression. Patients who did not fit either criterion were
included in the Stable group. Patients who initially had a
rising PSA value without clinical disease progression, and
subsequently showed a PSA decline of > 50%, were cate-
gorized as being in the PSA flare-up group, in accordance
with the Olbert et al’s [5] and Nelius et al’s series [4]. In the
subanalysis of patients receiving > 10 cycles of therapy, the
baseline PSA was defined as the level on the first of the 11th
cycle of chemotherapy. Treatment was continued until
serious or intolerable adverse events occurred. Adverse
events were classified according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events
version 4. Serious adverse events included intolerable pe-
ripheral sensory neuropathy and other fatal conditions such
as sepsis or impending hepatic failure.
Statistical analysis
A KaplaneMeier plot was used to estimate the OS proba-
bility between treatment groups. Log-rank test and Cox’s
proportional-hazards model were used to evaluate the
significance of additional cycles of treatment. Additionally,
the PSA response after chemotherapy was examined as a
secondary outcome. The Fisher’s exact test, Pearson’s Chi-
square test, and two-tailed independent t-test were car-
ried out with the SPSS software, version 17.0 to identify a
relationship between demographic and clinical variables,
occurrence of adverse events, and PSA response.
Results
Between October 2005 and May 2012, a total of 92 patients
received docetaxel chemotherapy in our institute. After
excluding the patients who were administered < 3 cycles of
chemotherapy, 73 patients met the eligible criteria and
their data were collected for analysis. There were 33 pa-
tients receiving  10 cycles and 40 patients receiving > 10
cycles (Table 1). Compared with the patients who received
 10 cycles, patients who received > 10 cycles were on
average, younger (70.0  8.1 vs. 74.4  7.6 years;
p Z 0.019) and had a longer follow-up (22.6  10.3 vs.
14.6  14.4 months; p Z 0.008). The baseline PSA was not
significantly different between the groups (544.6  1038.3
vs. 446.1  753.8; p Z 0.417), and neither were other
baseline characteristics irrespective of prior radiotherapy,
the extent of distant metastases, and the use of
Table 1 Baseline patient characteristics.
10 cycles >10 cycles p
Patient no. 33 40
Baseline characteristics
Mean age (y) 74.4  7.6 70.0  8.1 0.019
Follow up duration (mo) 14.6  14.4 22.6  10.3 0.008
No. of cycles (range) 6.6  2.3 (3e10) 19.3  7.8 (11e39) 0.000
ECOG performance 0e1, n (%) 30 (90.1) 35 (87.5) 0.643
Baseline PSA (ng/mL) 544.6  1038.3 446.1  753.8 0.417
Extent of disease, n (%)
Bone metastases 32 (97) 37 (92.5) 0.622
Lymph node metastases 7 (21.2) 15 (37.5) 0.131
Visceral metastasesa 2 (6.1) 3 (7.5) 1.0
Prior radiotherapy, n (%) 4 (12.1) 7 (17.5) 0.523
Concomitant bisphosphonate, number (n) 22 24 0.557
ECOG Z Eastern Cooperative Oncology Group; PSA Z prostate-specific antigen.
a Liver or lung metastases.
460 Y.-C. Shen et al.concomitant bisphosphonate. The average docetaxel
administration was 6.6 cycles and 19.3 cycles (range, 11e39
cycles, p < 0.001) in the patients receiving  10 cycles and
> 10 cycles, respectively. The median survival in patients
receiving  10 cycles and > 10 cycles was 13.4 months and
22.7 months, respectively, but there was no significant
difference in OS probability between the two groups (log-
rank test, p Z 0.75; Figure 1). Even after adjusting the
factor of age by Cox regression model, there was no dif-
ference in both groups (p Z 0.71). With respect to the
initial PSA response, 39.4% and 35% of patients’ PSA decline
of > 50% from baseline in the groups receiving  10 cycles
and > 10 cycles, respectively (p Z 0.752; Table 2).
Comparing the PSA response after the 11th cycle of
chemotherapy with initial PSA response in  10 cycles
group, there was only 17.5% patients having PSA decline >
50% but there was no statistical difference (p Z 0.109).
The adverse effects after docetaxel treatment are listed
in Table 3. There were more adverse events involving the
hepatobiliary system together with a higher incidence of
abnormal AST and ALT in patients who received > 10 cycles
of therapy (p Z 0.001 and p Z 0.014). One patient who
received 38 cycles of docetaxel suffered fatal hepaticFigure 1. KaplaneMeier curve of overall survival for patients
receiving  10 cycles and > 10 cycles of treatment.failure, which resulted in death. Peripheral sensory neu-
ropathy ( Grade 2) was also prominent in patients
receiving > 10 cycles of treatment (p Z 0.009). Among all
73 patients, 36 (49.3%) achieved a 50% PSA decline, 23
(31.5%) achieved PSA stabilization, and 14 (19.2%) had PSA
progression. In the responder group, six patients (8.2%) had
PSA flare-up without evidence of clinical deterioration or
disease progression. The median duration of the PSA surge
was 3 weeks (range, 3e12 weeks) and the median PSA surge
was 16.9% (range, 5.8e100%). The median survival was
37.1 months, 26.8 months, and 18.8 months in the PSA
flare-up, Responder, and Progression groups, respectively.
The OS in the Responder group was better than patients in
the Progression group (Figure 2A; pZ 0.036) and there was
no difference in OS between the Responder and PSA flare-
up groups (p Z 0.977; Figure 2B).Discussion
DP every 3 weeks has been established as first-line
chemotherapy for mCRPC, giving a modest 2e3-month
survival advantage over conventional palliative chemo-
therapy regimen in combination with prednisone according
to the TAX-327 study and a subsequent, updated report
[1,3]. However, the optimal number of cycles remains un-
clear. It is important to identify at which stage second-line
therapy should be initiated because new, second-line
agents also provide a substantial survival benefit [7,8].
The original design of the TAX-327 and SWOG 99-16 studies
on docetaxel treatment for mCRPC specified a maximum of
12 cycles due to toxicity concerns, and as a result little is
known regarding the outcomes of treating with > 10 cycles.
Prior to 2012, there was no therapeutic agent available
after docetaxel failure in our institute, and as a result, 40
patients (54.8%) received > 10 cycles of docetaxel; the
treatment only ended when serious or intolerable adverse
events occurred. Patients receiving > 10 cycles were on
average younger, possibly because this meant they could
tolerate chemotherapy better. The survival benefit was
good before 18 months, but there was no significant benefit
Table 2 Prostate-specific antigen (PSA) response in pa-
tients receiving  10 cycles or > 10 cycles of therapy.
10
cycles
>10 cycles
(after first
cycle)
>10 cycles
(after 11th
cycle)
p
Patient (n) 33 40 40
PSA response, n (%) 0.752a
PSA decline <50% 12
(36.4)
18 (45) 21 (52.5)
PSA progression 8
(24.2)
8 (20) 12 (30)
PSA decline 50% 13
(39.4)
14 (35) 7 (17.5)
a Between  10 cycles group and > 10 cycles (initial response
after first cycle).
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follow-up period. In the TAX-327 and SWOG 99-16 trials,
chemotherapy was withdrawn if there was disease pro-
gression or an unacceptable adverse event. Another ran-
domized, phase-2 trial conducted by Ascenta Therapeutics
(CS-205) allowed for up to 17 cycles of DP or a placebo, and
compared its use in combination with AT-101, a B-cell
lymphoma-2 antagonist [9]. A retrospective hypothesis-
generating analysis compared the TAX-327 and CS-205
studies and also concluded that there was no survival
benefit in men with mCRPC who received > 10 cycles of
docetaxel treatment [10].Table 3 Adverse events.
10 cycles >10 cycles p
(n Z 33) (n Z 40)
Hematologic system, n (%)
Anemia  Grade 3 18 (54.5) 22 (55) 0.969
Thrombocytopenia,
platelets < 105/mm3
12 (36.4) 18 (45) 0.455
Neutropenia,
ANC < 1500/mm3
8 (24.2) 13 (32.5) 0.438
Hepatobiliary system, n (%)
Abnormal AST 19 (57.6) 36 (90) 0.001
Abnormal ALT 8 (24.2) 21 (52.5) 0.014
Abnormal total bilirubin 7 (21.2) 11 (27.5) 0.535
Hepatic failure  Grade 2 0 (0) 1 (2.5) 1.0a
Gastrointestinal system, n (%)
Diarrhea  Grade 2 3 (9.1) 6 (15.0) 0.499a
Nausea/vomiting  Grade 2 9 (27.3) 18 (45.0) 0.118
Stomatitis  Grade 3 (9.1) 3 (7.5) 1.0a
Others, n (%)
Fatigue  Grade 2 9 (27.3) 18 (45.0) 0.118
Alopecia  Grade 2 5 (15.2) 14 (35.0) 0.054
Peripheral sensory
neuropathy  Grade 2
1 (3) 10 (25) 0.009
Treatment related death 0 (0) 1 (2.5) 1.0a
ALT Z aspartate aminotransferase; ANC Z absolute neutrophil
count; AST Z alanine aminotransferase.
a Fisher’s exact test.Generally, systemic cytotoxic chemotherapy for
advanced cancer is administered for no more than six cycles
due to toxicity concerns. Docetaxel is mainly metabolized
in the liver and has the potential to cause hepatocyte
damage and even severe fulminant hepatocellular necrosis
[11]. Elevated liver enzyme levels (AST and ALT) indicate
the severity of hepatocyte damage. In this study, there
were significantly more patients with abnormal AST and ALT
in the group treated with > 10 cycles for docetaxel, and the
severity of liver damage also increased. Peripheral sensory
neuropathy also occurred more frequently in patients
receiving an extended course of treatment due to the
higher cumulative dosage. Although some experts advo-
cated intermittent chemotherapy to reduce toxicity
[12e16], the impact of this on survival was unclear. It is
necessary to optimize the maximal number of docetaxel
treatment cycles in order to prevent bone marrow
exhaustion and other adverse events so that the patient can
benefit from second-line therapy.
Other than the maximal number of docetaxel therapy
cycles, we also addressed the minimum number of cyclesFigure 2. KaplaneMeier curve of overall survival between:
(A) prostate-specific antigen (PSA) progression and responder;
and (B) PSA flare-up and responder.
462 Y.-C. Shen et al.that could be effective. An initial PSA surge before a
therapeutic response is a known phenomenon androgen-
deprivation therapy in hormone sensitive prostate cancer.
This “flare” has also been reported in patients with doce-
taxel [4e6]. Due to a number of patients experiencing an
initial PSA flare-up phenomenon during docetaxel chemo-
therapy (ranging from 10% to 18%) [4e6,17,18], and as
previous studies have shown this does not have a negative
impact on survival [4e6], it means some patients would
present with initial PSA elevation possibly followed by a
subsequent response and had the same survival benefit with
the PSA response group. Stopping chemotherapy prema-
turely (before the 1st 12 weeks or four cycles) may allow
this group of patients to lose the chance of receiving sur-
vival benefits. Physicians should not cease chemotherapy
based only on an initial rise in PSA. Possible reasons for a
PSA flare-up include its release into the circulation from
acute tumor lysis, transactivation of mutated androgen
receptors by the estramustine component, the effects of
premedication with dexamethasone, and the increased
differentiation of cancer stem precursors [19,20]. We found
that the median duration of the PSA surge was 3 weeks and
the range was 3e12 weeks. At least four cycles of treat-
ment were advised, unless there were intolerable side ef-
fects or clinical disease progression, in order to prevent
premature exclusion of patients from a potentially benefi-
cial chemotherapy regimen. The Prostate Cancer Clinical
Trials Working Group-2 criteria also recommended at least
four cycles before evaluating the response due to this
concern [21]. We found no survival benefit with adminis-
tering > 10 cycles, which was related to an increased
number of adverse events. Therefore, proceeding to
second-line therapy or enrollment in another clinical trial
should be considered after approximately 10 cycles of
treatment, regardless of the PSA response. To the best of
our knowledge, the number of patients receiving > 10 cy-
cles exceeds that in other reports. We also suggest that the
bias related to treatment strategy can be minimized in a
report from a single institute. However, this study was
limited due to its retrospective nature, and potential bias
due to the lack of baseline equivalence in the patients
receiving different numbers of treatment cycles and vari-
ation of follow-up duration. A further randomized
controlled trial is necessary to compare extended doses of
docetaxel with other potential cytotoxic or biologic
therapies.
According this study, it suggests at least four cycles of
docetaxel for patients with mCRPC in order not to cease
treatment prematurely from potentially effective chemo-
therapy. Administering > 10 cycles of DP for 3 weeks does
not extend survival and results in more adverse effects.
Proceeding to a second-line therapy should not be retarded
by first-line docetaxel, especially when exceeding 10
cycles.
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